BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol. 2009;92:238-243. [PMID: 19454367 DOI: 10.1016/j.radonc.2009.04.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Shiomi M, Mori S, Shinoto M, Nakayama Y, Kamada T, Yamada S. Comparison of carbon-ion passive and scanning irradiation for pancreatic cancer. Radiotherapy and Oncology 2016;119:326-30. [DOI: 10.1016/j.radonc.2016.04.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Radiother Oncol 2015;114:122-7. [PMID: 25614389 DOI: 10.1016/j.radonc.2015.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
3 Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015;7:241-249. [PMID: 26483878 DOI: 10.4251/wjgo.v7.i10.241] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
4 Verma V, Lin SH, Simone CB 2nd, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol 2016;7:644-64. [PMID: 27563457 DOI: 10.21037/jgo.2016.05.06] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
5 Gupta P, Totti S, Pérez-mancera PA, Dyke E, Nisbet A, Schettino G, Webb R, Velliou EG. Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model. RSC Adv 2019;9:41649-63. [DOI: 10.1039/c9ra09123h] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Nichols RC, Huh SN, Prado KL, Yi BY, Sharma NK, Ho MW, Hoppe BS, Mendenhall NP, Li Z, Regine WF. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012;83:158-163. [PMID: 22245197 DOI: 10.1016/j.ijrobp.2011.05.045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
7 Buwenge M, Cilla S, Guido A, Giaccherini L, Macchia G, Deodato F, Cammelli S, Cellini F, Mattiucci GC, Valentini V, Stock M, Morganti AG. Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study. Rep Pract Oncol Radiother 2016;21:548-54. [PMID: 27708554 DOI: 10.1016/j.rpor.2016.09.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi JM. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev 2016;43:104-12. [PMID: 26827698 DOI: 10.1016/j.ctrv.2015.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
9 Overgaard J. Advancing radiation oncology through scientific publication – 100 volumes of Radiotherapy and Oncology. Radiotherapy and Oncology 2011;100:1-6. [DOI: 10.1016/j.radonc.2011.07.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Fukumitsu N, Okumura T, Hiroshima Y, Ishida T, Numajiri H, Murofushi KN, Ohnishi K, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers. Jpn J Radiol 2018;36:456-61. [DOI: 10.1007/s11604-018-0743-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol 2020;11:166-75. [PMID: 32175120 DOI: 10.21037/jgo.2019.03.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014;24:105-112. [PMID: 24635867 DOI: 10.1016/j.semradonc.2013.11.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
13 Guo XZ, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol. 2013;5:20-28. [PMID: 23556053 DOI: 10.4251/wjgo.v5.i2.20] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
14 Kim TH, Lee WJ, Woo SM, Kim H, Oh ES, Lee JH, Han SS, Park SJ, Suh YG, Moon SH, Kim SS, Kim DY. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Technol Cancer Res Treat 2018;17:1533033818783879. [PMID: 29962281 DOI: 10.1177/1533033818783879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bittner M, Grosu A, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer – A systematic review. Radiotherapy and Oncology 2015;114:117-21. [DOI: 10.1016/j.radonc.2014.11.043] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
16 Chuong M, Badiyan SN, Yam M, Li Z, Langen K, Regine W, Morris C, Snider J 3rd, Mehta M, Huh S, Rutenberg M, Nichols RC. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. J Gastrointest Oncol 2018;9:687-93. [PMID: 30151265 DOI: 10.21037/jgo.2018.03.14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
17 Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol 2016;46:885-92. [PMID: 27534798 DOI: 10.1093/jjco/hyw102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
18 Fontana G, Riboldi M, Gianoli C, Chirvase CI, Villa G, Paganelli C, Summers PE, Tagaste B, Pella A, Fossati P, Ciocca M, Baroni G, Valvo F, Orecchia R. MRI quantification of pancreas motion as a function of patient setup for particle therapy -a preliminary study. J Appl Clin Med Phys 2016;17:60-75. [PMID: 27685119 DOI: 10.1120/jacmp.v17i5.6236] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA. Radiotherapy Technical Considerations in the Management of Locally Advanced Pancreatic Cancer: American-French Consensus Recommendations. International Journal of Radiation Oncology*Biology*Physics 2012;83:1355-64. [DOI: 10.1016/j.ijrobp.2011.11.050] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
20 Kawashiro S, Mori S, Yamada S, Miki K, Nemoto K, Tsuji H, Kamada T. Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography. Br J Radiol 2017;90:20160790. [PMID: 28181819 DOI: 10.1259/bjr.20160790] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Strauss VY, Shaw R, Virdee PS, Hurt CN, Ward E, Tranter B, Patel N, Bridgewater J, Parsons P, Radhakrishna G, O'Neill E, Sebag-Montefiore D, Hawkins M, Corrie PG, Maughan T, Mukherjee S. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer 2019;19:121. [PMID: 30717707 DOI: 10.1186/s12885-019-5307-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Miki K, Mori S, Shiomi M, Yamada S. Gated carbon-ion scanning treatment for pancreatic tumour with field specific target volume and organs at risk. Physica Medica 2016;32:1521-8. [DOI: 10.1016/j.ejmp.2016.11.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
23 Huang J, Robertson JM, Margolis J, Balaraman S, Gustafson G, Khilanani P, Nadeau L, Jury R, Mcintosh B. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiotherapy and Oncology 2011;99:114-9. [DOI: 10.1016/j.radonc.2011.05.038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
24 Tseng YD, Wo JY, Ancukiewicz M, Adams J, Depauw N, Mamon HJ, Hong TS. Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer. J Radiat Oncol 2013;2:427-34. [DOI: 10.1007/s13566-013-0114-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Olsen DR, Overgaard J. Leveraging clinical performance by technological excellence – The case of particle therapy. Radiotherapy and Oncology 2010;95:1-2. [DOI: 10.1016/j.radonc.2010.03.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Miki K, Fukahori M, Kumagai M, Yamada S, Mori S. Effect of patient positioning on carbon-ion therapy planned dose distribution to pancreatic tumors and organs at risk. Physica Medica 2017;33:38-46. [DOI: 10.1016/j.ejmp.2016.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Thompson RF, Mayekar SU, Zhai H, Both S, Apisarnthanarax S, Metz JM, Plastaras JP, Ben-Josef E. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41:081711. [PMID: 25086521 DOI: 10.1118/1.4887797] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
28 Nichols RC, George TJ, Zaiden RA, Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncologica 2013;52:498-505. [DOI: 10.3109/0284186x.2012.762997] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
29 Sio TT, Merrell KW, Beltran CJ, Ashman JB, Hoeft KA, Miller RC, Whitaker TJ, Wurgler SK, Tryggestad EJ. Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study. Physica Medica 2016;32:331-42. [DOI: 10.1016/j.ejmp.2015.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
30 Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010;7:437-447. [PMID: 20628346 DOI: 10.1038/nrgastro.2010.98] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
31 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
32 Mori S, Shinoto M, Yamada S. Four-dimensional treatment planning in layer-stacking boost irradiation for carbon-ion pancreatic therapy. Radiotherapy and Oncology 2014;111:258-63. [DOI: 10.1016/j.radonc.2014.02.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]